A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

References

• Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 371–84
   PubMed Web of Science ®Google Scholar
• Kumano H, Kaiya H, Yoshiuchi K, Yamanaka G, Sasaki T, Kuboki T. Comorbidity of irritable bowel syndrome, panic disorder, and agoraphobia in a Japanese representative sample. Am J Gastroenterology 2004; 99: 370–6
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654–60
   PubMed Web of Science ®Google Scholar
• Camilleri M, Heading RC, Thompson WG. Consensus reports: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 1407–30
   PubMed Web of Science ®Google Scholar
• Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998; 42(6)845–9
   PubMed Web of Science ®Google Scholar
• Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganiere M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771–7
   PubMed Web of Science ®Google Scholar
• Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 Suppl 2: 15–30
   PubMed Web of Science ®Google Scholar
• Humphrey PPA, Bountra C, Clayton N, Kozlowski K. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13 Suppl 2: 31–8
   PubMed Web of Science ®Google Scholar
• Olden KW. Irritable bowel syndrome: An overview of diagnosis and pharmacologic treatment. Cleve Clin J Med 2003; 70 Suppl 2: S3–7
   PubMedGoogle Scholar
• Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetrin, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149–59
   PubMed Web of Science ®Google Scholar
• Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733–40
   PubMed Web of Science ®Google Scholar
• Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial. Lancet 2000; 355: 1035–40
   PubMed Web of Science ®Google Scholar
• Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterology 2001; 96: 2662–70
   PubMed Web of Science ®Google Scholar
• Jones RH, Holtmann G, Rodrigo L, Ensanullah RSB, Crompton PM, Jacques LA, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419–27
   PubMed Web of Science ®Google Scholar
• Miyata K, Kamato T, Nishida A, Katsuyama Y, Iwai A, Yuki H, et al. Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H- benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine 3 receptor antagonist, and its enantiomer in the isolated tissue. J Pharmacol Exp Ther 1991; 259: 15–21
   PubMed Web of Science ®Google Scholar
• Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc) 2002; 38: 75–89
   PubMed Web of Science ®Google Scholar
• Miyata K, Kamato T, Nishida A, Ito H, Yuki H, Yamamo M, et al. Role of the serotonin 3 receptor in stress-induced defecation. J Pharmacol Exp Ther 1992; 261: 297–303
   PubMed Web of Science ®Google Scholar
• Miyata K, Ito H, Fukudo S. Involvement of the 5-HT3 receptor in CRH-induced defecation in rats. Am J Physiol 1998; 274: G827–31
   PubMedGoogle Scholar
• Hirata T, Keto Y, Funatsu T, Sasamata M, Miyata K. Effects of ramosetron hydrochloride on defecation and abdominal pain in rats. Gastroenterology 2005; 128 Suppl 2: A466
   Web of Science ®Google Scholar
• Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A Phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Under review.
   Google Scholar
• Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007; 5: 534–40
   PubMed Web of Science ®Google Scholar
• Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology 2002; 123: 1686–701
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Cheskin LJ, Heller BR, Robinson JC, Crowell MD, Benjamin C, et al. Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology 1990; 98: 1485–9
   PubMed Web of Science ®Google Scholar
• Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002; 50: 471–4
   PubMed Web of Science ®Google Scholar
• Naliboff BD, Berman S, Chang L, Derbyshire SWG, Suyenobu B, Vogt BA, et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003; 124: 1738–47
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Center for Drug Evaluation and Research, Lotronex Pharmacology Review(s), http:: //www.fda.gov/cder/foi/nda/2000/21107a_Lotronex.htm.
   Google Scholar
• Berman S, Munakata J, Naliboff BD, Chang L, Mandelkern M, Silverman D, et al. Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain 2000; 4: 157–72
   PubMed Web of Science ®Google Scholar
• Berman SM, Chang L, Suyenobu B, Derbyshire SW, Stains J, Fitzgerald L, et al. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology 2002; 123: 969–77
   PubMed Web of Science ®Google Scholar
• Mawe GM, Coates MD, Moses PL. intestinal serotonin signalling in irritable bowel syndrome [review article]. Aliment Pharmacol Ther 2006; 23: 1067–76
   PubMed Web of Science ®Google Scholar
• Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657–64
   PubMed Web of Science ®Google Scholar
• Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 2004; 53: 1452–8
   PubMed Web of Science ®Google Scholar
• Camilleri M. Is there a SERT-a in association with IBS?. Gut 2004; 53: 1396–9
   PubMed Web of Science ®Google Scholar
• Tally NJ, Zinsmeister AR, Melton LJ III. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142: 76–83
   PubMed Web of Science ®Google Scholar
• Lotronex® tablets (prescribing information/product label).
   Google Scholar
• Suh DC, Kahler KH, Choi IS, Shin H, Kralstein J, Shetzline M. Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis. Aliment Pharmacol Ther 2007; 25: 681–92
   PubMed Web of Science ®Google Scholar